Non-vitamin K antagonist oral anticoagulants (NOACs) have proven a favorable risk-benefit
profile compared to vitamin K antagonists (VKAs) for preventing stroke and systemic …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) are at least non-inferior
to Vitamin K Antagonists (VKAs) for stroke prevention on patients with non-valvular atrial …

Background Non-vitamin K oral anticoagulants (NOACs) are proven alternatives to vitamin K
antagonists (VKAs) for the prevention of thromboembolism in patients with nonvalvular atrial …

Background: Scarce data are available about efficacy and safety of new oral anticoagulants
(NOACs) for cardioversion (CV) of atrial fibrillation (AF). We performed a meta-analysis of …

Background Current guidelines recommend anticoagulation using warfarin with bridging
parenteral anticoagulation or one of the non-vitamin K antagonist oral anticoagulants …

Background There are limited data on outcomes following cardioversion in atrial fibrillation
(AF) patients treated with non-vitamin K antagonist oral anticoagulants (NOACs). A meta …

Pharmacological or electrical cardioversion allows immediate symptoms improvement in the
setting of paroxysmal or persistent atrial fibrillation (AF), although the periprocedural risk of …

Background Non-vitamin K oral anticoagulants are now proven alternatives to vitamin K
antagonists for stroke prevention in atrial fibrillation. However, there are few data on the …

Background DOACs are increasingly used in patients with NVAF. Information on efficacy
and safety of these compounds in patients undergoing electrical or pharmacological …

Aim The aim of the present study was to assess the safety and effectiveness of non-vitamin K
antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in atrial …